Please note: The information displayed on this page might be outdated.
PAION AG: Remimazolam: short-acting anesthetic. Ph 3 study in procedural sedation in US. Safety data in ASA III/IV patients in Ph 3 colonoscopy study and Ph 3 bronchoscopy study. US approval filed by partner Cosmo Pharmaceuticals in June 2019. Initiated Ph 3 in general anesthesia in EU in July 2018, exp completion 2020.
Based in...
Clinical Stage
Phase III
Disease Space
Central Nervous System, Pain
Biotechnology, Specialty Pharmaceutical
Public, USA
Market Cap
100MM - 500MM
Martin Strasse 10
Aachen, Nordrhein-Westfalen 52062

Company Participants at Solebury Trout Virtual Global Healthcare Conference Series

  • James Phillips, CEO

Top 10 Holders of PAION AG

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
TIAA-CREF Investment Management LLC 2.86 1,826,453 5.39 Stakes 6/29/20
Baring Asset Management Ltd. 0.83 548,024 1.62 Funds 2/29/20
FPS Vermögensverwaltung GmbH 0.44 282,990 0.83 Funds 6/30/20
Lampe Asset Management GmbH 0.05 34,400 0.10 Funds 6/30/20
Baader Bank AG (Investment Management) 0.05 30,000 0.09 Funds 7/31/20
Gutmann Finanz Strategien AG 0.03 22,292 0.07 Funds 6/30/20
Wallberg Invest SA 0.02 11,000 0.03 Funds 12/31/19
Messieurs Hottinguer & Cie Gestion Privée SA 0.02 10,435 0.03 Funds 10/31/19
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.